id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-0770-0002,FDA,FDA-2020-D-0770,Best Practices in Developing Proprietary Names for Non-Prescription Drug Products; Guidance for Industry; Draft Guidance,Other,Guidance,2020-12-09T05:00:00Z,2020,12,2020-12-09T05:00:00Z,2021-02-09T04:59:59Z,2024-11-06T23:43:04Z,,1,0,090000648498f748
FDA-2020-D-0770-0001,FDA,FDA-2020-D-0770,Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2020-12-09T05:00:00Z,2020,12,2020-12-09T05:00:00Z,,2021-03-15T21:11:29Z,2020-27057,0,0,090000648498fbf4